jacmar: Regarding Lympro revenue guidance I believ
Post# of 30027
Posted On: 11/12/2014 8:52:54 AM
jacmar: Regarding Lympro revenue guidance I believe I remember you chiming in and saying it would be over 200 million in 2015. You chide me for having "concerns" so I think reminding you of the discrepancy between your estimate and Jason's one million dollar estimate is also fair.
We all thought things would be doing better than they have done. You're not alone in your expectations being too high. You don't seem to care that things haven't shaped up as we'd hoped, but is it not possible for you to understand those who do have concerns about it?
We all thought we'd be seeing LymPro data in the 90s instead of the 80s by now, and that we'd have a partner and be trading above .20 or .30 cents! Some thought based on Gerald's comments that we might not even need a reverse split because we'd be trading over $2.00!!!! How did those expectations get built?
That Gerald didn't feel the need to respond to Jason's 1:100 RS comment or his one million dollar 2015 revenue estimate.....does concern me. Jason is AMBS' only analyst. He has been our biggest promoter. For him to say our 2016 revenue for Lympro will only be in the 3.5 million range means either he has gone off the deep end, or we all have been way, way off in our LymPro expectations!!
Perhaps it is too early to assume AMBS is another AMGEN?
We all thought things would be doing better than they have done. You're not alone in your expectations being too high. You don't seem to care that things haven't shaped up as we'd hoped, but is it not possible for you to understand those who do have concerns about it?
We all thought we'd be seeing LymPro data in the 90s instead of the 80s by now, and that we'd have a partner and be trading above .20 or .30 cents! Some thought based on Gerald's comments that we might not even need a reverse split because we'd be trading over $2.00!!!! How did those expectations get built?
That Gerald didn't feel the need to respond to Jason's 1:100 RS comment or his one million dollar 2015 revenue estimate.....does concern me. Jason is AMBS' only analyst. He has been our biggest promoter. For him to say our 2016 revenue for Lympro will only be in the 3.5 million range means either he has gone off the deep end, or we all have been way, way off in our LymPro expectations!!
Perhaps it is too early to assume AMBS is another AMGEN?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼